The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The conflict is also triggering a widening public health emergency
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The approval comes after a systematic review of published literature
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Subscribe To Our Newsletter & Stay Updated
